Apolipoprotein E3 Active Protein | APOE3 active protein

Recombinant Human Apolipoprotein E3

Cat. Num. AAA140648

• Gene Names: APOE; AD2; LPG; APO-E; LDLCQ5
• Purity: Greater than 95% as determined by SDS-PAGE.
• Synonyms: Apolipoprotein E3; Recombinant Human Apolipoprotein E3; APOE3 Human; Apolipoprotein E3 Human Recombinant; Apolipoprotein E; LDLCQ5; APO-E; LPG; AD2; Alzheimer Disease 2 (APOE*E4-Associated; Late Onset); APOE; APOE3 active protein

• Host: E Coli
• Purity/Purification: Greater than 95% as determined by SDS-PAGE.
• Form/Format: (1.99mg/mL) sterile filtered solution supplied in 10mM MOPS, 50mM NaCL, 0.2% (w/v) CHAPS and 1mM TCEP, PH7.5
• Sequence: MHHHHHHKVE QAVETEPEPE LRQQTEWQSG QRWELALGRF WDYLRWVQTL SEQVQEELLS SQVTQELRAL MDETMKELKA YKSELEEQLT PVAEETRARL SKELQAAQAR LGADMEDVCG RLVQYRGEVQ AMLGQSTEEL RVRLASHLRK LRKRLLRDAD DLQKRLAVYQ AGAREGAERG LSAIRERLGP LVEQGRVRAA TVGSLAGQPL QERAQAWGER LRARMEEMGS RTRDRLDEVK EQVAEVRAKL EEQAQQIRLQ AEAFQARLKS WFEPLVEDMQ RQWAGLVEKV QAAVGTSAAP VPSDNH
• Sequence Length: 317

• Biological Activity: Immobilized rHuApoE3 binds to rMuVLDLR with EC50 less than 0.4 ug/ml.
• Physical Appearance: Sterile Filtered clear solution
• Solubility: It is recommended to reconstitute the lyophilized APOE in sterile 18M-cm H2O not less than 100 ug/ml, which can then be further diluted to other aqueous solutions.
• Preparation and Storage: Store at 4°C if entire vial will be used within 2-4 weeks.; Store, frozen at -20°C for longer periods of time.; For long term storage it is recommended to add a carrier protein (0.1% HSA or BSA).; Avoid freeze/thaw cycles.

Related Product Information for APOE3 active protein

Description: APOE3 Human Recombinant (19-317) produced in E Coli is a single, non-glycosylated, polypeptide chain containing 306 amino acids and having a molecular mass of 35kDa.The APOE is fused to a 7 amino acid His tag [M-HHHHHH] at N-terminus and purified by proprietary chromatographic techniques.

Product Categories/Family for APOE3 active protein

Cytokines and Growth Factors

NCBI and Uniprot Product Information

• NCBI GI #: 4557325
• NCBI GeneID: 348
• NCBI Accession #: NP_000032.1
• NCBI GenBank Nucleotide #: NM_000041.3
• UniProt Accession #: P02649; Q9P2S4; B2RC15; C0JYY5
• NCBI Official Full Name: apolipoprotein E isoform b
• NCBI Official Synonym Full Names: apolipoprotein E
• NCBI Official Symbol: APOE
• NCBI Official Synonym Symbols: AD2; LPG; APO-E; LDLCQ5
• NCBI Protein Information: apolipoprotein E
• UniProt Protein Name: Apolipoprotein E
• UniProt Gene Name: APOE
• UniProt Synonym Gene Names: Apo-E
• UniProt Entry Name: APOE_HUMAN

Uniprot Description

APOE: Mediates the binding, internalization, and catabolism of lipoprotein particles. It can serve as a ligand for the LDL (apo B/E) receptor and for the specific apo-E receptor (chylomicron remnant) of hepatic tissues. Defects in APOE are a cause of hyperlipoproteinemia type 3 (HLPP3); also known as familial dysbetalipoproteinemia. Individuals with HLPP3 are clinically characterized by xanthomas, yellowish lipid deposits in the palmar crease, or less specific on tendons and on elbows. The disorder rarely manifests before the third decade in men. In women, it is usually expressed only after the menopause. The vast majority of the patients are homozygous for APOE*2 alleles. More severe cases of HLPP3 have also been observed in individuals heterozygous for rare APOE variants. The influence of APOE on lipid levels is often suggested to have major implications for the risk of coronary artery disease (CAD). Individuals carrying the common APOE*4 variant are at higher risk of CAD. Genetic variations in APOE are associated with Alzheimer disease type 2 (AD2). It is a late-onset neurodegenerative disorder characterized by progressive dementia, loss of cognitive abilities, and deposition of fibrillar amyloid proteins as intraneuronal neurofibrillary tangles, extracellular amyloid plaques and vascular amyloid deposits. The major constituent of these plaques is the neurotoxic amyloid-beta-APP 40-42 peptide (s), derived proteolytically from the transmembrane precursor protein APP by sequential secretase processing. The cytotoxic C-terminal fragments (CTFs) and the caspase-cleaved products such as C31 derived from APP, are also implicated in neuronal death. The APOE*4 allele is genetically associated with the common late onset familial and sporadic forms of Alzheimer disease. Risk for AD increased from 20% to 90% and mean age at onset decreased from 84 to 68 years with increasing number of APOE*4 alleles in 42 families with late onset AD. Thus APOE*4 gene dose is a major risk factor for late onset AD and, in these families, homozygosity for APOE*4 was virtually sufficient to cause AD by age 80. The mechanism by which APOE*4 participates in pathogenesis is not known. Defects in APOE are a cause of sea-blue histiocyte disease (SBHD); also known as sea-blue histiocytosis. This disorder is characterized by splenomegaly, mild thrombocytopenia and, in the bone marrow, numerous histiocytes containing cytoplasmic granules which stain bright blue with the usual hematologic stains. The syndrome is the consequence of an inherited metabolic defect analogous to Gaucher disease and other sphingolipidoses. Defects in APOE are a cause of lipoprotein glomerulopathy (LPG). LPG is an uncommon kidney disease characterized by proteinuria, progressive kidney failure, and distinctive lipoprotein thrombi in glomerular capillaries. It mainly affects people of Japanese and Chinese origin. The disorder has rarely been described in Caucasians. Belongs to the apolipoprotein A1/A4/E family.

Protein type: Lipid-binding; Secreted; Secreted, signal peptide

Chromosomal Location of Human Ortholog: 19q13.2

Cellular Component: chylomicron; cytoplasm; early endosome; endoplasmic reticulum; extracellular matrix; extracellular region; extracellular space; Golgi apparatus; membrane; nucleus; plasma membrane

Molecular Function: antioxidant activity; beta-amyloid binding; cholesterol binding; cholesterol transporter activity; heparin binding; identical protein binding; lipid binding; lipid transporter activity; low-density lipoprotein receptor binding; metal chelating activity; phospholipid binding; protein binding; protein homodimerization activity; tau protein binding

Biological Process: cGMP-mediated signaling; cholesterol catabolic process; cholesterol efflux; cholesterol homeostasis; cholesterol metabolic process; cytoskeleton organization and biogenesis; fatty acid homeostasis; G-protein coupled receptor protein signaling pathway; intracellular transport; lipoprotein catabolic process; lipoprotein metabolic process; long-chain fatty acid transport; negative regulation of blood coagulation; negative regulation of blood vessel endothelial cell migration; negative regulation of cholesterol biosynthetic process; negative regulation of endothelial cell proliferation; negative regulation of inflammatory response; negative regulation of MAP kinase activity; negative regulation of neuron apoptosis; neurite regeneration; nitric oxide mediated signal transduction; phospholipid efflux; positive regulation of cGMP biosynthetic process; positive regulation of lipid biosynthetic process; positive regulation of low-density lipoprotein receptor catabolic process; positive regulation of membrane protein ectodomain proteolysis; positive regulation of nitric-oxide synthase activity; protein import; receptor-mediated endocytosis; regulation of axon extension; regulation of Cdc42 protein signal transduction; regulation of neuronal synaptic plasticity; retinoid metabolic process; reverse cholesterol transport; synaptic transmission, cholinergic; triacylglycerol catabolic process; triacylglycerol metabolic process; virus assembly

Disease: Alzheimer Disease 2; Alzheimer Disease 4; Lipoprotein Glomerulopathy; Macular Degeneration, Age-related, 1; Sea-blue Histiocyte Disease